Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Remodeling

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Bone Disorders

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Osteoclasts in Bone Remodeling

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Re: Bobelyak M, Vaculik J, Stepan JJ. Bone mineral density assessment using Radiofrequency Echographic Mult Spectrometry (REMS) in patients before and after total hip replacement, Osteoporos Int 2025;https://doi.org/10.1007/s00198-025-07685-w and Re: Pocock N, Chan D. Editorial: Is REMS-BMD truly a measured parameter? A call for transparency and technical clarification, Osteoporos Int 2025;https://doi.org/10.1007/s00198-025-07699-4.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2025

Same author

Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2023

Same author

Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2022

Same author

Patient preferences for lifestyle behaviours in osteoporotic fracture prevention: a cross-European discrete choice experiment.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2022

Same author

Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs.

Drugs·2020

Same author

The association between type 2 diabetes mellitus, hip fracture, and post-hip fracture mortality: a multi-state cohort analysis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2019

Search research articles

Related Experiment Videos

Treatment failure in osteoporosis.

A Diez-Perez¹, J D Adachi, D Agnusdei

¹Department of Internal Medicine and Infectious Diseases, Hospital del Mar-IMIM, Autonomous University of Barcelona, RETICEF, Instituto Carlos III, P. Maritim 25-29, 08003 Barcelona, Spain. adiez@parcdesalutmar.cat

Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

|July 28, 2012

Summary

Guidelines for defining treatment failure in fracture risk reduction therapies are provided. Failure may be indicated by multiple fractures, unsuppressed bone remodeling markers, or decreasing bone mineral density.

Related Experiment Videos

Area of Science:

Osteoporosis research
Clinical guidelines
Pharmacological interventions

Background:

Fracture risk reduction therapies are crucial in osteoporosis management.
Defining treatment failure is essential for optimizing patient care and therapeutic strategies.
Current criteria for treatment failure lack standardization, leading to clinical uncertainty.

Purpose of the Study:

To establish clear guidelines for defining the failure of therapies aimed at reducing fracture risk.
To provide clinicians with pragmatic criteria for assessing treatment efficacy.
To address an unmet clinical need in osteoporosis management.

Main Methods:

Convening a working group of the International Osteoporosis Foundation's Committee of Scientific Advisors.
Defining key outcome variables to aid clinical decision-making.
Reviewing existing evidence and expert consensus.

Main Results:

Treatment failure can be inferred from multiple incident fractures (two or more) during therapy.
Failure is suggested if bone remodeling markers remain unsuppressed by anti-resorptive therapy.
Continued decrease in bone mineral density despite treatment indicates potential failure.

Conclusions:

The established criteria offer pragmatic definitions for treatment failure in fracture risk reduction.
These guidelines address a critical clinical need and can guide therapeutic adjustments.
The defined criteria are expected to stimulate further research in this important area.